Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension

Published April 8, 2023
by Eclipsebio

Intro text lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Grants

02
12
26

2026 mRNA Innovators Award Call for Applications

The mRNA Innovators Award offers matching funds to design and validate a therapeutic of interest using Eclipsebio's design models and characterization methods.

Eclipsebio's closed-loop RNA drug discovery platform

eBlogs

02
07
26

The power of pairing RNA design and analytics

Discover how closed-loop RNA development pairs design and sequencing to accelerate better therapeutics.

Press Releases

01
26
26

Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics

Originally posted on Business Wire SAN DIEGO, January 26, 2026 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, today announced the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics. The acquisition accelerates Eclipsebio’s strategy to deliver an integrated, data-first platform to support RNA […]

eBlogs

01
15
26

Achieving regulatory requirements by measuring IVT RNA integrity

As RNA therapeutics and regulatory requirements advance, validation methods for IVT RNA integrity are advancing as well.

Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension

Related articles

2026 mRNA Innovators Award Call for Applications

The power of pairing RNA design and analytics

Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics

Achieving regulatory requirements by measuring IVT RNA integrity